Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …

Lung cancer continues to be the leading cause of cancer-related death worldwide. In the last
decade, significant advancements in the diagnosis and treatment of lung cancer, particularly …

PURPOSE Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase
inhibitor, is currently approved for the treatment of patients with RET fusion–positive non …

Lung cancer, of which non-small lung cancer is the most common subtype, represents the
leading cause of cancer related-death worldwide. It is now recognized that a significant …

Rearranged during transfection (RET) receptor tyrosine kinase was first identified over thirty
years ago as a novel transforming gene. Since its discovery and subsequent pathway …

Simple Summary Non-small cell lung cancer (NSCLC) remains a significant cause of death
worldwide, despite the significant progresses to date. Multiple molecular alterations have …

The objective of this narrative review is to summarize the efficacy and safety of available
therapies for rearranged during transfection (RET) fusion-positive non-small cell lung cancer …

Rearranged during transfection (RET) is a protooncogene that encodes for receptor tyrosine
kinase with downstream effects on multiple cellular pathways. Activating RET alterations can …

Abstract The Rearranged during Transfection (RET) oncogene has been extensively
investigated in solid malignancies, particularly thyroid cancer and non-small cell lung cancer …

Selpercatinib, a first-in-class, highly selective and potent central nervous system-active RET
kinase inhibitor demonstrated clinically meaningful activity with manageable toxicity in …